<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>600(7)</volume><submitter>Southam K</submitter><pubmed_abstract>Accurate modelling type 2 diabetes and diabetic complications in rodents has proven a challenge, largely as a result of the long-time course of disease development in humans. In the present study, we aimed to develop and comprehensively characterise a new rodent model of type 2 diabetes. To do this, we fed Sprague-Dawley rats a high fat/high sugar diet (HFD) to induce obesity and dyslipidaemia. After 3 weeks, we s.c. implanted osmotic mini pumps to enable a 14 day, slow infusion of streptozotocin (STZ; lower dose = 100 mg kg&lt;sup>-1&lt;/sup> ; higher dose = 120 mg kg&lt;sup>-1&lt;/sup> ) to dose-dependently reduce pancreatic beta cell mass. After removing the mini pumps, we monitored animals for 4 months using a battery of tests to assess both metabolic and neurodegenerative changes across time. Our</pubmed_abstract><journal>The Journal of physiology</journal><pagination>1611-1630</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9541365</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Development and characterisation of a rat model that exhibits both metabolic dysfunction and neurodegeneration seen in type 2 diabetes.</pubmed_title><pmcid>PMC9541365</pmcid><pubmed_authors>Southam K</pubmed_authors><pubmed_authors>de Sousa C</pubmed_authors><pubmed_authors>Premilovac D</pubmed_authors><pubmed_authors>Taylor BV</pubmed_authors><pubmed_authors>Daniel A</pubmed_authors><pubmed_authors>Foa L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development and characterisation of a rat model that exhibits both metabolic dysfunction and neurodegeneration seen in type 2 diabetes.</name><description>Accurate modelling type 2 diabetes and diabetic complications in rodents has proven a challenge, largely as a result of the long-time course of disease development in humans. In the present study, we aimed to develop and comprehensively characterise a new rodent model of type 2 diabetes. To do this, we fed Sprague-Dawley rats a high fat/high sugar diet (HFD) to induce obesity and dyslipidaemia. After 3 weeks, we s.c. implanted osmotic mini pumps to enable a 14 day, slow infusion of streptozotocin (STZ; lower dose = 100 mg kg&lt;sup>-1&lt;/sup> ; higher dose = 120 mg kg&lt;sup>-1&lt;/sup> ) to dose-dependently reduce pancreatic beta cell mass. After removing the mini pumps, we monitored animals for 4 months using a battery of tests to assess both metabolic and neurodegenerative changes across time. Our</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-04-05T20:11:47.059Z</modification><creation>2025-04-05T20:11:47.059Z</creation></dates><accession>S-EPMC9541365</accession><cross_references><pubmed>35128667</pubmed><doi>10.1113/JP282454</doi></cross_references></HashMap>